A systematic review and network meta-analysis, which allowed the simultaneous comparison of multiple achieved systolic blood pressure (SBP) levels on clinical outcomes while preserving trial-level treatment randomization, indicates that treating patients to reduce SBP below currently recommended targets may significantly reduce risk of cardiovascular disease (CVD) and all-cause mortality, with the lowest risk at a SBP of 120 to 124 mm Hg. The study included 144 220 patients from 42 trials. In general, there were linear associations between mean achieved SBP and risk of CVD and mortality, with the lowest risk at 120 to 124 mm Hg. Randomized groups with a mean achieved SBP of 120 to 124 mm Hg had a hazard ratio (HR) for major CVD of 0.71, 0.58, 0.46 and 0.36, respectively, compared with randomized groups with a mean achieved SBP of 130 to 134 mm Hg, 140 to 144 mm Hg, 150 to 154 mm Hg, and 160 mm Hg or more. Likewise, randomized groups with a mean achieved SBP of 120 to 124 mm Hg had an HR for all-cause mortality of 0.73, 0.59, 0.51 and 0.47, respectively, compared with randomized groups with a mean achieved SBP of 130 to 134 mm Hg, 140 to 144 mm Hg, 150 to 154 mm Hg, and 160 mm Hg or more. The findings support more intensive control of SBP among adults with hypertension. Source: http://jamanetwork.com/http://jamanetwork.com/
Children and adolescents who regularly consume sugar-sweetened beverages (SSBs) and fruit juice may face a…
Women who consistently performed resistance training had a substantially lower risk of major cardiovascular disease…
US Adults with prediabetes who participated in an intensive lifestyle intervention had a significantly lower…
The impact of late-life high blood pressure (BP) on dementia risk appears to depend on…
A U.S. study found that receiving the recombinant herpes zoster vaccine (RZV, shingles vaccine) was…
A pooled analysis of 11 prospective cohort studies involving more than 1.5 million adults found…
This website uses cookies.